



Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,
Rasoolpura, Secunderabad - 500 003, INDIA.
Tel : +91 40 6657 5454, 2790 3226
Fax : +91 40 2790 8708
Website : www.vantabio.com
Email : info@vantabio.com
CIN No. : U74999TG2016PLC109280

To,
The Listing Department,
BSE Ltd.

November 09, 2018

Sub: Outcome of Board Meeting held on November 09, 2018.

We wish to inform you that the Board Directors of the Company, at their just concluded meeting have inter alia, transacted the following businesses:

1. Approved the un-audited financials for the half year ended September 30, 2018 and took note of the limited review report issued by the statutory auditors.
2. Took note of incorporation of 100 % subsidiary "Vanta Clinical Research Limited" and also 51 % step down subsidiary "Vayam Research Solutions Limited"


Please find enclosed

- The unaudited financial results for half year ended September 30, 2018 along with the limited review report issued by the statutory auditors of the Company.
- Press release in connection with incorporation of WOS - "Vanta Clinical Research Limited"

The meeting commenced at 11.30 A.M. and concluded at 5:00 P.M.

This for your information and dissemination to the public.

For VANTA BIOSCIENCE LIMITED
Scrip Code: 540729 I Scrip ID: VANTABIO


SADHANALA VENKATA RAO
CEO & Whole Time Director
DIN: 02906370





MATHESH & RAMANA
CHARTERED ACCOUNTANTS

Review Report to the Board of Directors of **VANTA BIOSCIENCE LIMITED**.

We have reviewed the accompanying statement of unaudited financial results of M/s Vanta Bioscience Limited for the period of six months ended on 30th September, 2018. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements Issued by the Institute of Chartered Accountants of India. This standard required that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 including the manner in which is to be disclosed, or that it contains any material misstatement.

For **MATHESH AND RAMANA**
CHARTERED ACCOUNTANTS



B. V. RAMANA REDDY
M.No. 026967 Partner

Place: Hyderabad
Date: 09.11.2018

E-mail : matheshca@yahoo.co.in

3-6-145, Himayatnagar, Hyderabad - 500 029. Ph: 2322 1822 / 2322 6993 / 2322 2863



Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,
Rasoolpura, Secunderabad - 500 003, INDIA.
Tel : +91 40 6657 5454, 2790 3226
Fax : +91 40 2790 8708
Website : www.vantabio.com
Email : info@vantabio.com
CIN No. : U74999TG2016PLC109280

VANTA BIOSCIENCE LIMITED
UMAJAYA COMPLEX, RASOOLPURA, SECUNDERABAD

UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2018

Rs. In Lakh (Except share data)					
Sl. No	Particulars	Half Year Ended		Year Ended	
		Six Months Ended	Preceding 6 Months Ended (01.10.2017 to 31.03.2018)	Corresponding Six months ended in the previous year on 30.09.2017	Preceding Year Ended
		30.09.2018	31.03.2018	30.09.2017	31.03.2018
		Unaudited	Audited	Un Audited	Audited
	Revenue				
1	Revenue from Operations	602.22	349.25	49.35	398.60
2	Other Income	7.56	5.28	-	5.28
3	Total Revenue(1+2)	609.78	354.53	49.35	403.88
4	Expenses				
	a) Cost of material Consumed	75.89	27.64	4.62	32.26
	b) Purchase of Stock In trade	0	0	0	0
	trade	0	0	0	0
	d) Employee Benefit Expenses	181.38	149.31	11.80	161.11
	e) Finance Cost	79.32	15.80	3.84	19.64
	f) Depreciation and Amortization Exp	36.29	40.84	16.38	57.22
	g) other Expenses	191.07	95.73	6.42	102.15
		563.95	329.32	43.06	372.38
5	Profit Before Exceptional and Extraordinary Items (3-4)	45.83	25.21	6.29	31.50
6	Exceptional Items	0	0	0	0
7	Profit Before Extraordinary Items (5-6)	45.83	25.21	6.29	31.50
8	Extraordinary Items	0	0	0	0
9	Profit Before Tax(7+8)	45.83	25.21	6.29	31.50
10	Tax Expenses				
	a) Current Tax	8.82	4.80	1.20	6.00
	b) Deffered Tax	7.71	15.32	7.45	22.77
11	Profit/(loss) for the period from continuing Operations (9-10)	29.30	5.09	-2.36	2.73
12	Profit/(loss) Discontinuing Operations	0	0	0	0
13	Tax Expenses of Discontinuing Operations	0	0	0	0
14	Profit/(loss) from Discontinuing Operations (12+13)	0	0	0	0
15	Profit & loss for the Period (11+14)	29.30	5.09	-2.36	2.73
16	Earning Per Share of Rs. 10 Each (Not Anualised)				
	a)Basic(Rs.)	0.51	0.09	-	0.05
	b) Diluted (Rs.)	0.51	0.09	-	0.05

For VANTA BIOSCIENCE LIMITED

M. Dopesha Raja

DOPESH RAJA MULAKALA

MANAGING DIRECTOR

DIN: 01176660

Secunderabad

9th November 2018



For VANTA BIOSCIENCE LIMITED

S. Venkatesh Rao

VENKATA RAO SADHANALA

CEO & WHOLE TIME DIRECTOR

DIN: 02906370

Secunderabad

Research Center

K2-B, 11th Cross Street, SIPCOT Industrial Complex,
Gummidipoondi, Thiruvallur District, Tamilnadu - 601 201.
Tel : 044 6790 1600



Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,
Rasoolpura, Secunderabad - 500 003, INDIA.
Tel : +91 40 6657 5454, 2790 3226
Fax : +91 40 2790 8708
Website : www.vantabio.com
Email : info@vantabio.com
CIN No. : U74999TG2016PLC109280

VANTA BIOSCIENCE LIMITED
NO.02/G/308/G NO.3/FF/SF/1-20-248,UMAJAY COMPLEX, RASOOLPURA, SECUNDERABAD -
500003, TELANGANA

STATEMENT OF ASSETS AND LIABILITIES AS ON 30.09.2018		
Rs. In Lakh (Except share data)		
Particulars	As at 30.9.2018	As at 31.03.2018
1. Equity and Liabilities		
I. Share holder's Funds		
a)Share capital	572.80	572.80
b)Reserves & Surplus	1,115.23	1,085.93
	1,688.03	1,658.73
II. Non Current Liabilities		
a)Deffered Tax liabilities (Net)	30.48	22.76
b)Long term Borrowings	1,103.92	998.01
c) Long term provisions	0	0
	1,134.40	1,020.77
III. Current Liabilities		
a) Short Term Borrowings	54.19	119.85
b) Trade payables		
A.) Total Outstanding dues of Micro Enterprises & Small		
B.) Total Outstanding dues of Creditors Other Than		
Micro Enterprises & Small Enterprises	34.02	19.43
c) other Current Liabilities	71.35	94.34
d) Short Term Provisions	9.31	6.00
	168.87	239.62
Total	2,991.30	2,919.12
2. Assets		
I. Non Current Assets		
a) Fixed Assets		
Tangible Assets	1,509.60	1,497.10
Research & Development	531.68	486.23
b)Other Non current Assets	35.04	35.04
	2,076.32	2,018.37
II. Current Assets		
a) Current investments	150.00	450.00
b)Inventories	569.67	302.44
c)Trade Receivable	52.37	33.02
d)Cash & Bank Bal	7.91	8.73
e)Short Term Loans & Advances	80.54	54.75
f)Other Current Assets	54.49	51.80
	914.98	900.75
Total	2,991.30	2,919.12

For VANTA BIOSCIENCE LIMITED

ni. Dapah Raja

DOPESH RAJA MULAKALA
MANAGING DIRECTOR
DIN: 01176660
Secunderabad
9th November 2018



For VANTA BIOSCIENCE LIMITED

S. Venkatesh R

VENKATA RAO SADHANALA
CEO & WHOLE TIME DIRECTOR
DIN: 02906370
Secunderabad
9th November 2018



Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,
 Rasoolpura, Secunderabad - 500 003, INDIA.
 Tel : +91 40 6657 5454, 2790 3226
 Fax : +91 40 2790 8708
 Website : www.vantabio.com
 Email : info@vantabio.com
 CIN No. : U74999TG2016PLC109280

Notes:

- The above said financial results were reviewed by the Audit committee and approved by the Board of Directors at their meeting held on 9th November 2018.
- As per MCA Notification dated 16th February 2015, the companies whose shares are listed on BSE SME platform as referred to in chapter XB of SEBI (Issue of capital and Disclosure requirements) regulations, 2009 are exempted from the compulsory requirement of adoption of IND-AS. As the company is covered under exempted from the compulsory requirement of adoption of IND AS. Hence it has not adopted IND AS for preparation of Financial Statements.
- Statement of Assets and Liabilities as on 30th September 2018 is enclosed herewith
- There were no investor complaints received/pending as at 30th September 2018
- The financial figures for the previous half year/year have been regrouped/reclassified, wherever necessary to confirm to current period.
- We hereby inform that there was no deviation in the utilization of public issue proceeds from the objects as stated in the prospectus of the issue, as required under regulation 32(1)(a) of the SEBI (Listing Obligations and Disclosure requirement) Regulation, 2015

Category	Amount in Lakhs	
	Projected utilization of Funds(As per offer documents)	Actual Utilization of Funds
Augmenting additional working capital requirement	679.40	529.40
General Corporate Purpose	26.60	26.60
Public Issue Expenses	50.00	50.00
Total	756.00	606.00

7.The statement includes figures of half year ended March 31, 2018 being the balancing figure between the audited figures in respect of the full financial year and the unaudited figures of the previous half year.

8. The Company is engaged in the business of full service preclinical contract Research organization. Hence there is no separate segment reporting required

9.During the year Company incorporated a fully owned subsidiary in the name and style of Vanta Clinical Research Limited on Dt.12/09/2018. Under this subsidiary, Company will carry out the business of Clinical Research viz., Bio equivalence, Bio Analytical studies, Phase studies (I - IV), Pharmacovigilance and Medical Writing activities.

For VANTA BIOSCIENCE LIMITED

For VANTA BIOSCIENCE LIMITED



DOPESH RAJA MULAKALA
 MANAGING DIRECTOR
 DIN: 01176660
 Secunderabad
 9th November 2018





VENKATA RAO SADHANALA
 CEO & WHOLE TIME DIRECTOR
 DIN: 02906370
 Secunderabad
 9th November 2018

Press Release

Vanta Bioscience Limited completes the process of expansion into Clinical Research

Hyderabad. November 09, 2018. The Board of Vanta Bioscience Limited announced completed the process of its expansion into Clinical Research Business. Vanta Bio Science Limited incorporated a wholly owned subsidiary under the name and style "Vanta Clinical Research Limited" on 12th September 2018. This subsidiary will carry out the business of clinical research. This was announced in a Board Meeting here today.

Mr. S. Venkat Rao, CEO and whole time Director of Vanta Bioscience Limited shared that this is in continuation to earlier announcement to capitalise the new business opportunity in the field of Clinical Research services. This Subsidiary will carry out the business of Clinical research i.e. bio-equivalence, bio-analytical studies, clinical trials, pharmacovigilance, medical writing etc. Going forward, Vanta Clinical Research Limited is expected to be Company's biggest money spinner and is expected to add Rs. 250 crores to Company's top line by year 2024-25, through organic and inorganic means

The Company has already appointed Promotor Director to head this subsidiary. He has more than three decades of experience in Clinical Research having set up similar facilities for some of the industry majors. The new subsidiary is likely to start contributing to top line during the last quarter of current financial year.

The Board of Directors was also apprised that Company's growth plan also included proposing to set up a full-fledged Analytical Services as a separate vertical within the Company. The Analytical Services are also expected contribute significantly to the revenues of the Company in near future.

For more information, kindly contact:

Priya Panvekar
Raka Reputation Management Services Pvt. Ltd.
Mobile: 7045654080



S. Venkat Rao

S. Venkat Rao

Vanta Bioscience Limited

Mobile: 9866272052